We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inspira (IINN) Expands in Life Support Space With New Deal
Read MoreHide Full Article
Inspira Technologies OXY (IINN - Free Report) has announced a partnership with Ennocure MedTech, a player in the field of bio-electronic wound dressing. This collaboration aims to integrate bio-electronic technology into Inspira's INSPIRA ART, a cutting-edge approach to oxygenating blood directly to replace traditional mechanical ventilation.
Financial terms of the deal have not been disclosed.
Addressing Unmet Needs of Bloodstream Infection Care
This collaboration particularly aims to address a persistent global healthcare challenge, with an estimated 250,000 bloodstream infections linked to intravenous lines annually. These infections not only result in prolonged hospital stays but also increase healthcare costs significantly.
Inspira's plan is to incorporate Ennocure's bio-electronic technology into its INSPIRA ART, creating a preventive approach to reduce complications and combat bloodstream infections.
Strategic Implications
According to Inspira, the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions will help the company improve patient outcomes in ICUs. This will, therefore, pave the way for safer and more effective life support treatments.
Image Source: Zacks Investment Research
Market Prospects
Going by a Data Bridge Market Research report, the global life support equipment market, valued at $4.25 billion in 2022, is projected to reach $6.96 billion by 2030, at a CAGR of 7.20%. Dominated by hospitals, the market's growth will be fueled by technological advancements, increasing healthcare expenditure and a rise in chronic diseases. Factors such as continuous innovation, improving healthcare infrastructure, and strategic collaborations are likely to further expand opportunities in this vital healthcare sector.
Share Price Performance
Over the past year, shares of IINN have lost 10.8% compared with the industry’s 8% decline.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it came up with an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have lost 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an earnings surprise of 47.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inspira (IINN) Expands in Life Support Space With New Deal
Inspira Technologies OXY (IINN - Free Report) has announced a partnership with Ennocure MedTech, a player in the field of bio-electronic wound dressing. This collaboration aims to integrate bio-electronic technology into Inspira's INSPIRA ART, a cutting-edge approach to oxygenating blood directly to replace traditional mechanical ventilation.
Financial terms of the deal have not been disclosed.
Addressing Unmet Needs of Bloodstream Infection Care
This collaboration particularly aims to address a persistent global healthcare challenge, with an estimated 250,000 bloodstream infections linked to intravenous lines annually. These infections not only result in prolonged hospital stays but also increase healthcare costs significantly.
Inspira's plan is to incorporate Ennocure's bio-electronic technology into its INSPIRA ART, creating a preventive approach to reduce complications and combat bloodstream infections.
Strategic Implications
According to Inspira, the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions will help the company improve patient outcomes in ICUs. This will, therefore, pave the way for safer and more effective life support treatments.
Image Source: Zacks Investment Research
Market Prospects
Going by a Data Bridge Market Research report, the global life support equipment market, valued at $4.25 billion in 2022, is projected to reach $6.96 billion by 2030, at a CAGR of 7.20%. Dominated by hospitals, the market's growth will be fueled by technological advancements, increasing healthcare expenditure and a rise in chronic diseases. Factors such as continuous innovation, improving healthcare infrastructure, and strategic collaborations are likely to further expand opportunities in this vital healthcare sector.
Share Price Performance
Over the past year, shares of IINN have lost 10.8% compared with the industry’s 8% decline.
Zacks Rank and Key Picks
Inspira currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Insulet (PODD - Free Report) , Haemonetics (HAE - Free Report) and DexCom (DXCM - Free Report) . While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it came up with an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have lost 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an earnings surprise of 47.1%.